The Cellular Electrophysiologic Effect of A New Amiodarone Like Antiarrhythmic Drug GYKI 16638 in Undiseased Human Ventricular Muscle: Comparison With Sotalol And Mexiletine
Abstract:The cellular electrophysiologic effect of GYKI 16638, a new antiarrhythmic compound was studied and compared with that of sotalol and mexiletine in undiseased human right ventricular muscle preparation by applying the conventional microelectrode technique.
GYKI 16638 (5 M), at stimulation cycle length of 1000 ms, lengthened action potential duration (APD90) from 338.9 ± 28.6 ms to 385.4 ± 24 ms (n = 9, p< 0.05). This APD lengthening effect, unlike that of sotalol (30 M), was rate-independent. GYKI 16638, contrary to sotalol and like mexiletine (10 M), exerted a use-dependent depression of the maximal rate of depolarization (Vmax) which amounted to 36.4 ± 11.7 percent at cycle length of 400 ms (n = 5, p p< 0.05) and was characterised with an offset kinetical time constant of 298.6 ± 70.2 ms.
It was concluded that GYKI 16638 in human ventricular muscle shows combined Class IB and Class III antiarrhythmic properties, resembling the electrophysiological manifestation seen after chronic amiodarone treatment.
Document Type: Review Article
Publication date: January 1, 2002
More about this publication?
- Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.